Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine

J Clin Neurosci. 2022 Feb:96:85-89. doi: 10.1016/j.jocn.2021.12.016. Epub 2022 Jan 6.


The slow-channel congenital myasthenic syndrome is an autosomal dominant neuromuscular disorder caused by mutations in different subunits of the acetylcholine receptor. Fluoxetine, a common antidepressant and long-lived open-channel blocker of acetylcholine receptor, has been reported to be beneficial in the slow-channel congenital myasthenic syndrome. Here we report a prospective open label study of fluoxetine treatment in some affected members of a Thai family with slow-channel congenital myasthenic syndrome caused by a novel p.Gly153Ala (c.518G > C) mutation in CHRNA1 in the AChR α subunit. These patients showed significant clinical improvement following fluoxetine treatment but their respiratory function responded variably.

Keywords: Fluoxetine; Slow-channel congenital myasthenic syndrome; Thai; Treatment.

MeSH terms

  • Fluoxetine* / therapeutic use
  • Humans
  • Mutation
  • Myasthenic Syndromes, Congenital* / drug therapy
  • Myasthenic Syndromes, Congenital* / genetics
  • Prospective Studies
  • Receptors, Cholinergic / genetics
  • Thailand


  • Receptors, Cholinergic
  • Fluoxetine